Dr. Geall Joins the Company’s World-class Scientific Advisors in Cardiology, Vaccine Development and Human Genetics CAMBRIDGE, Mass.–(BUSINESS WIRE)–Verve Therapeutics, a next-generation cardiovascular company developing therapies that safely edit the adult human genome to permanently reduce a person’s risk of coronary artery disease, today announced the appointment of Andrew Geall, […]
Other News
Alnylam Pharmaceuticals Announces Initiation of APOLLO-B Phase 3 Study of Patisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
– APOLLO-B Will Enroll Patients with Both Hereditary and Wild-Type Amyloidosis – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company has initiated APOLLO-B, a global Phase 3 placebo-controlled clinical trial of patisiran, an intravenously administered RNAi therapeutic, for the treatment of transthyretin […]
Resverlogix Provides Update on BETonMACE Phase 3 Trial
Top-line results projected to be available on or about September 30, 2019 Number of MACE increases from 250 to greater than 275 CALGARY, Alberta, Sept. 16, 2019 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today that, following the completion of final patient safety visits (as reported […]
BioCardia Announces Positive DSMB Recommendation to Continue Phase 3 Pivotal CardiAMP Heart Failure Study as Planned
SAN CARLOS, Calif., Sept. 16, 2019 (GLOBE NEWSWIRE) — BioCardia (Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the Phase III pivotal CardiAMP Heart Failure Trial, which included safety […]
Neovasc Announces Changes to its Board of Directors
Norman Radow, Managing Partner at Strul Medical Group, Joins Company’s Board NASDAQ, TSX: NVCN VANCOUVER, Sept. 16, 2019 /PRNewswire/ – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the […]
Proximo Medical Named the Commercialization Partner for BIOTRONIK, Inc.’s Peripheral Vascular Intervention Portfolio in Select U.S. Markets
CASTLE PINES, Colo., Sept. 16, 2019 /PRNewswire/ — Proximo Medical, LLC today announced that it is the commercial partner for BIOTRONIK, Inc.’s peripheral vascular intervention (PVI) platform in select United States markets. BIOTRONIK, a global medical technology company headquartered in Berlin, Germany with U.S. offices in New York City and Lake Oswego, Oregon, develops trusted and innovative cardiovascular and endovascular solutions. Proximo Medical is […]
BioVentrix Announces the Appointment of Pedro Marques as VP of Sales in Europe
SAN RAMON, Calif., Sept. 16, 2019 /PRNewswire/ — BioVentrix, Inc., a pioneer of technologies and procedures for the less invasive treatment of heart failure (HF), announced today that Pedro Marques has been named Vice President of Sales for the European market. The addition of Mr. Marques to a key leadership position marks another milestone in […]
Intact Vascular to Announce One-Year Data from TOBA III Clinical Trial
Study Investigates Use of the Tack Endovascular System® for Focal Dissection Repair Following Drug-Coated Balloon Angioplasty in PAD Patients WAYNE, Pa.–(BUSINESS WIRE)–Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that the one-year data from its Tack Optimized Balloon Angioplasty (TOBA) III clinical trial will be presented during […]
FDA Grants Fast Track Designation for FARXIGA in Heart Failure
WILMINGTON, Del.–(BUSINESS WIRE)– AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of FARXIGA (dapagliflozin) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure in adults with heart failure with reduced ejection fraction (HFrEF) or […]
Microbot Medical Announces Outcome of Annual Meeting of Shareholders
Maintains Regulatory Pre-Submission Timeline of the Self-Cleaning Shunt (SCS TM) HINGHAM, Mass., Sept. 13, 2019 (GLOBE NEWSWIRE) — Having successfully executed a number of significant milestones over the past twelve months, Microbot Medical Inc. (NASDAQ: MBOT) held its 2019 annual shareholders’ meeting on September 10, 2019, during which the shareholders re-elected three […]



